Evidence map›Paper›PMID 28537433›Full record

ArticleAntioxidants & redox signaling2017

Aspirin-Mediated Acetylation Protects Against Multiple Neurodegenerative Pathologies by Impeding Protein Aggregation.

Srinivas Ayyadevara, Meenakshisundaram Balasubramaniam, Samuel Kakraba, Ramani Alla, Jawahar L Mehta, Robert J Shmookler Reis

Abstract read
In one paragraph

Article in Antioxidants & redox signaling, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed.

  1. Targeting cGAS-STING and Ferroptosis in Aortic Disease: Another Aspirin Discovery.Arteriosclerosis, thrombosis, and vascular biology · 2026
    Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Posttranslational Modifications ofPharmacological reviews · 2024
    Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Protein homeostasis in the aged and diseased heart.The journal of cardiovascular aging · 2023
    Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Srinivas Ayyadevara1 Central Arkansas Veterans Healthcare System, Research & Development Service , Little Rock, Arkansas.
Meenakshisundaram Balasubramaniam1 Central Arkansas Veterans Healthcare System, Research & Development Service , Little Rock, Arkansas.
Samuel Kakraba3 Bioinformatics Program, University of Arkansas for Medical Sciences, and University of Arkansas at Little Rock , Little Rock, Arkansas.
Ramani Alla1 Central Arkansas Veterans Healthcare System, Research & Development Service , Little Rock, Arkansas.
Jawahar L Mehta1 Central Arkansas Veterans Healthcare System, Research & Development Service , Little Rock, Arkansas.
Robert J Shmookler Reis1 Central Arkansas Veterans Healthcare System, Research & Development Service , Little Rock, Arkansas.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsMany progressive neurological disorders, including Alzheimer's disease (AD), Huntington's disease, and Parkinson's disease (PD), are characterized by accumulation of insoluble protein aggregates. In prospective trials, the cyclooxygenase inhibitor aspirin (acetylsalicylic acid) reduced the risk of AD and PD, as well as cardiovascular events and many late-onset cancers. Considering the role played by protein hyperphosphorylation in aggregation and neurodegenerative diseases, and aspirin's known ability to donate acetyl groups, we asked whether aspirin might reduce both phosphorylation and aggregation by acetylating protein targets.

resultsAspirin was substantially more effective than salicylate in reducing or delaying aggregation in human neuroblastoma cells grown in vitro, and in Caenorhabditis elegans models of human neurodegenerative diseases in vivo. Aspirin acetylates many proteins, while reducing phosphorylation, suggesting that acetylation may oppose phosphorylation. Surprisingly, acetylated proteins were largely excluded from compact aggregates. Molecular-dynamic simulations indicate that acetylation of amyloid peptide energetically disfavors its association into dimers and octamers, and oligomers that do form are less compact and stable than those comprising unacetylated peptides. INNOVATION: Hyperphosphorylation predisposes certain proteins to aggregate (e.g., tau, α-synuclein, and transactive response DNA-binding protein 43 [TDP-43]), and it is a critical pathogenic marker in both cardiovascular and neurodegenerative diseases. We present novel evidence that acetylated proteins are underrepresented in protein aggregates, and that aggregation varies inversely with acetylation propensity after diverse genetic and pharmacologic interventions.

conclusionsThese results are consistent with the hypothesis that aspirin inhibits protein aggregation and the ensuing toxicity of aggregates through its acetyl-donating activity. This mechanism may contribute to the neuro-protective, cardio-protective, and life-prolonging effects of aspirin. Antioxid. Redox Signal. 27, 1383-1396.

Indexed as

AcetylationAnimalsAspirinCaenorhabditis elegansCell LineDisease Models, AnimalHumansMolecular Dynamics SimulationNeurodegenerative DiseasesPhosphorylationProtein AggregatesProteinsAspirinProtein AggregatesProteinsaspirin (acetylsalicylic acid)inflammationneurodegeneration(protein) acetylation(protein) aggregation(protein) phosphorylation

Identifiers

PMID28537433
PMCPMC5661865

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.